Guías de Manejo Prehospitalario y Hospitalario y de Tratamiento de los Síndromes Coronarios Agudos con Elevación del Segmento del ST (SCACEST) en Terapia Intensiva y Unidades de Emergencia
Barra lateral del artículo
Contenido principal del artículo
Resumen
El tratamiento del Síndrome Coronario Agudo Con Elevación del ST comienza en el domicilio del paciente o en la sala de emergencia de la Institución donde concurre el paciente con un SCACEST ya que el tiempo es oro y la reperfusión precoz de la arteria culpable del infarto es la piedra angular del tratamiento del SCACEST y por lo tanto, todas las medidas que se lleven a cabo para lograr que la reperfusión sea lo más precoz posible deberán ser realizadas porque se ha demostrado que la restauración precoz del flujo coronario produce la reducción del tamaño del infarto, minimiza el daño miocárdico, preserva la función ventricular, disminuye la morbimortal cardiovascular.
Detalles del artículo
La revista no retiene los derechos de reproducción (copyright) por lo que los autores pueden volver a publicar sus trabajos con la sola mención a la fuente original de publicación.
Citas
• ACC/AHA Task Force on Practice Guidelines, Canadian Cardiovascular Society. ACC/AHA Guidelines for the Management of Patients with ST Elevation Myocardial Infarction-Executive Summary: Report of the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with AMI). Circulation 2004; 110: 588-636.
• Universal definition of myocardial infarction. Thygesen K, Alpert J, White H on behalf of the Joint ESC/ACCF/AHA/ WHF Task Force for the Redefinition of Myocardial Infarction. Eur Heart J 2007; 28: 2525-38.
• Braunwald E, Zipes D, Bonow R, Mann D, Libby P. Textbook of Cardiovascular Medicine Braunwald’s Heart Disease 8th ed, 2008. Chapter 50 and 51
• Lee K, Woodlief L, Topol E et al. Predictors of 30days mortality in the era of reperfusion for AMI. Results from an international trial of 41021 ptes. GUSTO-I. Circulation 1995; 91: 1659-68.
• Fox K, Dabbous O, Goldberg RJ et al. Prediction of risk of death and myocardial infarction in the six months after presentation with ACS: prospective, multinational, observational study (GRACE). BMJ 2006; 333: 1091-4.
• Morrow D, Antman E, Chasrleswork A et al. TIMI risk score for ST elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarction myocardium early trial sub-study. Circulation 2000; 102: 2031-7.
• Management of acute myocardial infarction in patients presenting with persistent ST segment elevation. The Task Force on the management of ST segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart Journal 2008; 29: 2909-45.
• Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled. Lancet 2005; 366: 1607-21.
• Von Beckerath N, Taubert D, Pogotsa Murray G et al. Absortion, metabolization and antiplatelet effects of 300, 600 and 900mg loading doses of clopidogrel results ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choosen between 3 High oral doses for immediate Clopidogrel Effect)Trial. Circulation 2005; 112: 2946-50.
• Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Eng J Med 2005; 352: 1179.
• Montalescot G, Sidris G, Meuleman C et al. A randomized comparison of high clopidogrel loading doses in patients with non ST segment elevation ACS: the ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial. J Am Coll Cardiol 2006; 48: 931-8.
• 12. Taher T, Fu Y, Wagner Gs et al. Aborted myocardial infarction in patients with ST segment elevation: insight from the assessment of the safety and efficacy of a New Trombolytic Regimen-3 Trial Electrocardiographic Substu-dy. J Am Coll Cardiol 2004; 44: 38-43.
• Gersh BJ, Antman EM. Selection of the optimal reperfusion strategy for STEMI: does time matter) Eur Heart J 2006; 27: 761-3.
• Steg PG, Bonnefoy E, Chabaud S et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-6.
• Henry TD, Atkins JM, Cunningham MS et al. ST Segment Elevation Myocardial Infarction: Recommendations on Triage of Patients to Heart Attack Centers. Is it Time for a National Policy for the Treatment of ST-Segment Elevation Myocardial Infarction? J Am Coll Cardiol 2006; 47: 1339-45.
• Barbash G, Birnbaum Y, Bogaerts K et al. Treatment of reinfarction after thrombolytic therapy for AMI: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO I) and assessment of the safety of a new thrombolytic (ASSENT 2) studies. Circulation 2001; 103: 954-60.
• Gershick A, Stephens Lloyd A, Hughes S et al. Rescue angioplasty after failed thrombolytic therapy for AMI. N Engl J Med 2005; 353: 2758-68.
• Di Mario C, Dudek D, Piscione F et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab Reteplase Stent Study in AMI (CARESS-AMI) an open, prospective, randomized, multicentre trial. Lancet 2008; 371: 559-68.
• Jacobs A, Antman EM, Ellrodt G et al. Recommendation to develop strategies to increase the number of ST-Segment-Elevation Myocardial Infarction Patients with timely access to primary percutaneous coronary intervention. The American Heart Association’s Acute Myocardial Infarction (AMI) Advisory. Circulation 2006; 113: 2152-63.
• Primary vs Tenecteplase facilitated percutaneous coronary intervention in patients with ST segment elevation AMI (ASSENT-4 PCI) randomized trial. Lancet 2006; 367: 569-78.
• Ellis SG, Tendera M, de Belder MA et al. Facilitated PCI in patients with STEMI. FINESSE Investigators. N Engl J Med 2008; 358: 2205-17.
• Van‘t Hof A, Ten Berg J, Heestermans T et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised contro-lled trial. Lancet 2008; 372: 537-46.
• Alexander KP, Newby LK, Armstrong PW et al. Acute Coronary Care in the Elderly, Part II ST segment elevation infarction. A Scientific Statement for Healthcare Professionals from the AHA council on Clinical Cardiology in collaboration with the Society of Geriatric Cardiology; Cir-culation 2007; 115: 2570-89.
• Wijeysundera HC, Vijayaraghavan R, Nallamothu BK et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST- segment myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol 2007; 49: 422-30.
• Fernandez Aviles F; Alonso J; Pena G et al. Primary angioplasty vs. early routine post fibrinolysis angioplasty for AMI with ST segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J 2007; 28: 949-60.
• Edmond J, French JK, Aylward PE et al. Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2. Eur Heart J 2007; 28: 1418-24.
• The CREATE Trial Group Investigators Effects of Reviparin, a Low Molecular Weight Heparin, on Mortality, Reinfarction, and Strokes in patients with Acute Myocardial Infarction presenting with ST Segment Elevation. JAMA 2005; 293: 427-36.
• Antman E, Morrow D, Mc Cabe et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST elevation myocardial infarction N Eng J Med 2006; 354:1477-88.
• The safety and efficacy of subcutaneous enoxaparin versus intravenous heparin and tirofiban versus placebo in the treatment of Acute ST- Segment Elevation Myocardial Infarction ineligible for reperfusion. J Am Coll Card 2003;
-56.
• Gibbons R, Fuster V. Therapy for patients with Acute Coronary Syndromes: New Opportunities. N Engl J Med 2006;
-7.
• Stone G, Witzenbichler B., Guagliumi G, et al HORIZONS-AMI Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008: 358: 2218-30.
• GISSI-3. Effects of lisinopril and transdermal glyceryl tri-nitrate singly and together on 6 week mortality and ventricular function after AMI. Lancet 1994; 343: 1115-22.
• A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium in 58050 patients with suspected AMI. ISIS-4 (FOURTH Inter-national Study of Infarct Survival Collaborative Group). Lancet 1995; 345: 669-85.
• Pfeffer MA, McMurray JJ, Velazuez EJ et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure left ventricular dysfunction or both. N Eng J Med 2003; 349: 1893-1906.
• Pitt B, Remme W, Neaton J et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dys-function after myocardial infarction. N Eng J Med 2003; 1309-21.
• Sarnak M, Levey A, Schoolwerth A et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Pre-vention. Hypertension 2003; 42: 1050-65.
• Anavekar N, Mc Murray J, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-95.
• Assali A, Brosh D, Ben-Dor I et al. The impact of renal insufficiency on patients outcomes in emergent angioplasty for AMI. Catheter Cardiovasc Interv 2007; 69: 395-400.
• Donahoe S, Stewart G, McCabe C et al. Diabetes and Mortality following ACS. JAMA 2007; 298: 765-75.
• Mak K, Moiterno D, Granger C et al. Influence of diabetes mellitus on clinical outcome in the trhombolytic era of AMI. GUSTO-I Investigators. J Am Coll Cardiol 1997; 30: 171-9.
• Mc Guire D, Emanuelsson H, Granger C et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of ACS Findings from the GUSTO-IIb study. GUSTO IIb Investigators Eur Heart J 2000; 21: 1750-8.
• Hafner S, Letho S, Rônnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctio. N Engl J Med 1998; 339: 229-34.
• Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 2001;225-35.
• Cao J, Hudson M, Jankowski et al. Relation of chronic and acute glycemic control on mortality in AMI with diabetes mellitus. Am J Cardiol 2005; 96: 183-6.
• Malmberg K, Northammar A, Wedel H et al. Glycometabolic state at administration important risk marker of mortality in conventionally treated patients with diabetes mellitus and AMI long term results from the Diabetes and Insulin-glucose infusion in AMI (DIGAMI) study. Circulation 1999;2626-32.
• Deedwania P, Kosiborod M, Barrett E et al. Hyperglycemia and ACS. A Scientific Statement from the AHA Diabetes
committee of the Council on Nutrition, Physical Activity and Metabolism. Circulation 2008; 117: 1610-9.
• Svensson A, McGuire D, Abrahamsson P et al. Association between hyper and hypoglycaemia and 2 year all cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005; 26: 1245-8.
• Sarnk M, Levey A, Schoolwerth A et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the AHA Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology and Epidemiology and Prevention. Hyper-tension 2003; 42:1050-65.
• Assali A, Brosh D, Ben-Dor I et al. The impact of renal insufficiency on patients outcomes in emergent angioplasty for AMI. Catheter Cardiovascular Interv 2007; 69: 395-400.
• Anavekar N, McMurray J, Velazquez E. et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004: 351: 1285-95.
• ACC/AATS/AHA/ASE/ASNC/SCAI/ SCCT/STS 2016 Appropriate Use Criteria for Coronary Revascularization in Patients With Acute Coronary Syndromes A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons JACC VOL. 69, NO. 5, 2017
• Wiviott SD, et al. Prasugrel vs clopidogrel in patients with acute coronary sÃndromes N Engl J Med 2007; 357: 2001–2015.
• Roe MT, et al. Prasugrel vs clopidogrel for acute coronary syndromes without revascularisation. N Engl J Med 2012; 367: 1297–1309.
• Montalescot G, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999–1010.
• Wallentin L, et al. Ticagrelor vs clopidogrel in patients with acute coronary sÃndromes N Engl J Med 2009; 361: 1045–1057.
• 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions . J Am Coll Card 2013;61:485-510
• Gibson CM, et al. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 2011; 161: 815–821 e6.
• Lip GY, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155–3179.
• Almendro-Delia M, et al. Prognostic impact of atrial fibrillation in acute coronary syndromes: results from the ARIAM registry. Eur Heart J Acute Cardiovasc Care 2014; 3: 141–148.
• Lip GY, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13–28.